Cited by 163Neuroinflammation and Neurodegeneration MechanismsAlzheimer's disease research and treatmentsFatty Acid Research and Health

Aspirin-Triggered Lipoxin A4 Stimulates Alternative Activation of Microglia and Reduces Alzheimer Disease–Like Pathology in Mice

Open access
Medeiros, Rodrigo, Kitazawa, Masashi, Passos, Giselle F., Baglietto-Vargas, David, Cheng, David, Cribbs, David H., LaFerla, Frank M.·2013·The American Journal of Pathology

Abstract

Microglia play an essential role in innate immunity, homeostasis, and neurotropic support in the central nervous system. In Alzheimer disease (AD), these cells may affect disease progression by modulating the buildup of β-amyloid (Aβ) or releasing proinflammatory cytokines and neurotoxic substances. Discovering agents capable of increasing Aβ uptake by phagocytic cells is of potential therapeutic interest for AD. Lipoxin A4 (LXA4) is an endogenous lipid mediator with potent anti-inflammatory properties directly involved in inflammatory resolution, an active process essential for appropriate host responses, tissue protection, and the return to homeostasis. Herein, we demonstrate that aspirin-triggered LXA4 (15 μg/kg) s.c., twice a day, reduced NF-κB activation and levels of proinflammatory cytokines and chemokines, as well as increased levels of anti-inflammatory IL-10 and transforming growth factor-β. Such changes in the cerebral milieu resulted in recruitment of microglia in an alternative phenotype, as characterized by the up-regulation of YM1 and arginase-1 and the down-regulation of inducible nitric oxide synthase expression. Microglia in an alternative phenotype-positive cells demonstrated improved phagocytic function, promoting clearance of Aβ deposits and ultimately leading to reduction in synaptotoxicity and improvement in cognition. Our data indicate that activating LXA4 signaling may represent a novel therapeutic approach for AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ajpath.2013.01.051

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Deficiency of FPR2 or administration of its inhibitors/anti-inflammatory ligands alleviates pathological symptoms of AD, including reduced activation of glial cells and tau hyperphosphorylation, and ultimately improves cognitive function.

    “Deficiency of FPR2 or administration of its inhibitors/anti-inflammatory ligands could alleviate the pathological symptoms of AD, including reduced activation of glial cells (microglia and/or astrocytes) and tau hyperphosphorylation, and ultimately leading to improvement in cognitive function [151–154].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Medeiros, R., Kitazawa, M., Passos, G. F., Baglietto-Vargas, D., Cheng, D., Cribbs, D. H., & LaFerla, F. M.
Affiliations
University of California, Irvine (US)
Corresponding author
LaFerla, Frank M.
Venue
The American Journal of Pathology
Publisher
Elsevier BV
Published
2013-05
Volume
182
Issue
5
Pages
1780-1789
ISSN
0002-9440 (ISSN-L)
OpenAlex
W2171245653
Cited by
163
References
60
Citations by year
2025: 3 · 2024: 13 · 2023: 10 · 2022: 17 · 2021: 20 · 2020: 14 · 2019: 16 · 2018: 14 · 2017: 22 · 2016: 11 · 2015: 11 · 2014: 9 · 2013: 3
FWCI
6.35
Type
journal article
Language
en
Open access
Locations
  • American Journal Of Pathology (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Alzheimer's Association
  • National Institutes of Health (AG00538, AG16573)
  • U.S. Public Health Service (R01NSO20989)
  • University of California, Irvine (P50 AG16573)
  • National Institute on Aging (P01AG000538, R01AG020335, P50 AG 16573, AG 00538, P50AG016573, R01AG20335)
  • National Institute of Neurological Disorders and Stroke
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (K99AR054695)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
Keywords
lipoxin A4, Alzheimer's disease, neuroinflammation, amyloid-beta clearance, phagocytosis, NF-κB, inflammatory cytokines, IL-10, TGF-beta, Ym1, arginase-1, inducible nitric oxide synthase, synaptotoxicity, cognitive enhancement, anti-inflammatory lipid mediators
MeSH terms
Alzheimer Disease, Animals, Aspirin, Astrocytes, Brain, Cognition, Male, Mice, Inbred C57BL, Phenotype, Protein Processing, Post-Translational, Synapses, Amyloid beta-Peptides, NF-kappa B, Microglia, Neuroprotective Agents, Lipoxins, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review